Eli Lilly's Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
CompanyDrug

Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes

3SBio's 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China
CompanyDrug

3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development
CompanyDeals

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development

La Prairie Holistic Health's Functional Nutrient Product Approved in Hainan Pilot Zone
Company

La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone

GSK's Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59
CompanyDrug

GSK’s Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy
CompanyDrug

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy

Medtronic's Implantable Defibrillator System Gains NMPA Approval in China
CompanyMedical Device

Medtronic’s Implantable Defibrillator System Gains NMPA Approval in China

Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study
CompanyDrug

Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study

Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice
CompanyDeals

Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice

Junion Therapeutics Secures RMB 100 Million Series A Financing for Weight Loss Device
CompanyDeals

Junion Therapeutics Secures RMB 100 Million Series A Financing for Weight Loss Device

Eli Lilly BigHat Biosciences Machine Learning Platform
CompanyDeals

Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies

Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer
CompanyDrug

Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer